Posted in M&A / Deals Novartis targets Xolair successor in buyout of startup Excellergy March 27, 2026 BioPharma Dive Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche s popular medicine. M&A / DealsImmunology & InflammationRead full story